Objective: This study investigated whether gross tumor volume of the primary tumor before treatment was a predictor for local recurrence in patients with resectable sinonasal tract squamous cell carcinoma who were treated by chemoradiotherapy. Methods: A total of 24 patients were enrolled. Pretreatment gross tumor volume of primary tumor was assessed by palpitation, perception and imaging. The cut-off value of the gross tumor volume for local recurrence was determined by receiver-operating curve analysis. A log-rank test and Cox's proportional hazards model were used for univariate and multivariate analyses with adjustment for the clinical T category (cT1-T4a/cT4b), respectively. Results: In the univariate analysis, patients with the gross tumor volume ≥83.7 ml were significantly associated with shorter local recurrence-free rate (P = 0.0023) and disease-free survival (P = 0.0064) than those with gross tumor volume <83.7 ml. In the multivariate analysis, gross tumor volume ≥83.7 ml were significantly associated with shorter local recurrence-free rate (P = 0.041). Conclusions: Pretreatment gross tumor volume of primary tumor ≥83.7 ml was significantly associated with local recurrence-free rate in resectable sinonasal tract squamous cell carcinoma.
Introduction
Squamous cell carcinoma (SCC) in the sinonasal tract, which is accounted for about 3% of malignant tumors in the head and neck, is widely treated by intravenous or intra-arterial chemoradiotherapy (CRT) as non-surgical definitive treatment (1) (2) (3) . Clinical and imaging methods have been investigated as useful predictors of survival outcomes in sinonasal tract SCC (2) (3) (4) . In a recent study, the authors reported that the Charlson comorbidity index (CCI) was significantly associated with overall survival (OS) and distant metastasis-free survival (DMFS) in 79 patients with sinonasal tract SCC treated by surgery or radiotherapy with or without chemotherapy (2) .
Gross tumor volume of the primary tumor (GTVp) before CRT has been reported in several studies to be a significant predictor for survival outcomes such as local recurrence-free rate (LRFR) in head and neck cancer (5) (6) (7) (8) (9) . However, to our best knowledge, the association between GTVp and survival outcomes has not previously been investigated in individuals with only sinonasal tract SCC.
In the present study, we investigated whether the pretreatment GTVp before CRT was a predictor for survival outcomes in sinonasal tract SCC.
Patients and methods

Patients
Between February 2007 and November 2014, 28 patients newly diagnosed as sinonasal tract SCC with resectable disease received CRT at the Department of Head and Neck Surgery, Aichi Cancer Center Hospital (2) . Among the 28 patients, three patients were excluded because of a total dose <60 Gy and 1 patient because of insufficient images. A total of 24 patients were enrolled in the study, and the study was approved by review board in our institution with informed consent for treatment and examination obtained from all of the patients.
Clinical parameters
The clinical staging, CCI, body mass index, selection of primary treatment modality, radiotherapy procedures, chemotherapy regimens and follow-up were previously described (2) . To summarize, clinical staging was based on the Union for International Cancer Control Classification of Malignant Tumours (Seventh edition). The CCI, which was a weighted index, was calculated by 19 comorbid conditions. Treatment selection for CRT included patients who did not want to have surgery. Definitive radiotherapy was a total dose of 69.9 ± 1.96 Gy (mean ± standard deviation [SD]), with 2-2.5 Gy per fraction. The chemotherapy regimen for 14 patients was intravenous platinum-based CRT, and for 10 patients, it was intraarterial platinum-based CRT. Following CRT, patients with early locoregional recurrence identified, and salvage surgery was performed.
Gross tumor volume of the primary tumor
Radiation oncologist delineated GTVp. The method of the measurement for GTVp (ml) was previously described (10) . Briefly, a Pinnacle workstation (Pinnacle Treatment System; Philips, Milpitas, CA, USA) or MIM Maestro (MIM Software, Inc., Cleveland, OH, USA) was used, and GTVp was assessed by palpitation, perception and imaging such as computed tomography (CT), magnetic resonance imaging and 18 F-fluorodeoxyglocose positron emission tomography with or without CT. In this study, the relationship between GTVp and clinical parameters is shown in Table 1 .
Study design and statistical analysis
Statistical analyses were performed by using the JMP software package (Version 9; SAS; Cary, NC, USA). The cut-off value of GTVp for local recurrence was determined by receiver-operating curve (ROC) analysis, as described previously (5) . The relationship between two groups (GTVp ≥ 83.7 or <83.87 ml) regarding the clinical parameters (age, sex, primary site, clinical T and N category, clinical stage, chemotherapy, body mass index and CCI) were compared by Fisher's exact test. Survival time as the duration between the endpoint of radiotherapy to survival event was calculated by the Kaplan-Meier method. The survival event was death for OS, local recurrence for LRFR, regional recurrence for regional recurrence-free survival (RRFS), distant metastasis for DMFS, and recurrence or distant metastasis for disease-free survival (DFS). Local recurrence was defined as disease recurrence at the primary tumor site, as describe previously (11). We did not count death as event of LRFR. A univariate survival analysis was compared by a log-rank test. A multivariate analysis adjusted for GTVp (<83.7 /≥83.7 ml) and clinical T category (cT1-T4a/cT4b) was performed using a Cox's hazards model. A P value of <0.05 was considered statistically significance.
Results
Clinical course
At the end of the study, the follow-up period (mean ± SD) for the whole population, the surviving 12 patients (50%) and the 12 patients who died (50%) were 41.7 ± 33.4, 70.8 ± 18.2 and 12.5 ± 12.2 months, respectively. Ten (41.7%), 1 (4%), 1 (4%) and 11 (45.8%) patients exhibited local recurrence, regional recurrence, distant metastasis, and recurrence or distant metastasis, respectively. By the end of the study, the rate of OS, LRFR, RRFS, DMFS and DFS in the whole study population was 49.7, 30.5, 95.8, 95.8 and 28.6%, respectively.
Cut-off value of GTVp
The GTVp (mean ± SD) of all patients was 69.3 ± 55.0 (range: 13.05-221.22) ml. ROC, area under the curve of the ROC, sensitivity and 1-specificity are shown in Fig. 1 . These measures were calculated for various GTVp comparing the presence of local recurrence with the absence of local recurrence. A cut-off value of GTVp (83.7 ml) was selected by the ROC analysis.
Univariate survival analysis
Patients were divided into two groups based on the GTVp (83.7 ml). Patients with GTVp ≥ 83.7 ml (n = 6) were significantly associated with shorter LRFR (P = 0.0023) and DFS (P = 0.0064) than those with GTVp < 83.7 ml (n = 18). However, in patients with GTVp ≥ 83.7 ml, the differences for OS (P = 0.43), RRFS (P = 0.08) and DMFS (P = 0.56) were not statistically significant. The KaplanMeier curves from the univariate analyses of LRFR and DFS are shown in Fig. 2 .
GTVp and clinical parameters
The relationships between two groups (GTVp ≥ 83.7 or <83.87 ml) regarding the clinical parameters were compared by Fisher's exact test (Table 2) . Patients with GTVp ≥ 83.7 ml were more frequently found to be cT4b than those with GTVp < 83.7 ml (P = 0.018).
Multivariate survival analysis
The results of the multivariate analyses of LRFR and DFS are shown in Table 3 . In the multivariate analysis with adjustments for clinical T category (cT1-T4a/cT4b), patients with GTVp ≥ 83.7 ml were significantly associated with shorter LRFR (P = 0.041). The association between GTVp and the survival of 24 patients with SCC in the sinonasal tract (Kaplan-Meier method). GTVp ≥ 83.7 ml was found to be associated with a significantly lower local recurrence-free rate (P = 0.0023) (A) and DFS (P = 0.0064) (B) by log-rank test. SCC, squamous cell carcinoma; DFS, disease-free survival. 
Discussion
The present study shows, for the first time, that patients of sinonasal tract SCC with GTVp ≥ 83.7 ml have significantly shorter LRFR by univariate and multivariate analyses. Sinonasal tract SCC rarely accounts for <1% of malignant tumors (1) . Although the TNM classification is widely used as a predictor in sinonasal tract SCC, it is sometimes difficult to predict the survival outcomes for patients with the same TNM classification of disease (2) .
Because the insufficiency of blood supply to the center of larger tumor leads to difficult delivery to chemotherapy agent, favorable microenvironment for rapid proliferation of hypoxic cells and low sensitivity to radiotherapy (6,7), we considered that GTVp ≥ 83.7 ml influences to local recurrence.
Higher GTVp before CRT is shown in several studies to be a significant predictor for survival outcomes in head and neck SCC (5-9). For example, Wu et al. reported that GTVp ≥ 49 ml, with the cut-off value determined by ROC analysis for local recurrence, was significantly associated with local control and DFS in laryngeal cancer (6) . As for sinonasal tract SCC, Doweck et al. reported that higher GTVp was significantly associated with shorter local control in 64 patients with head and neck SCC, including sinonasal tract SCC (7) . The findings of the present study show that higher GTVp is significantly associated with LRFR and DFS, which agrees with the findings of previous studies (5) (6) (7) (8) (9) . On the basis of the present study, our treatment strategy for patients with higher GTVp will include adjuvant chemotherapy and close monitoring during follow-up for salvage surgery.
Shiao et al. reported almost axiomatically that patients with larger tumors have worse outcomes. Specifically, they determined that high GTVp in head and neck cancer treated with CRT was a poor predictor of outcomes (9) . To our best knowledge, the association between GTVp and survival outcomes, such as LRFR, has not previously been investigated in only sinonasal tract SCC. Thus, we determined that there was a need for such an analysis.
The information of the association between GTVp and survival outcomes in sinonasal tract cancer of the present study is useful for head and neck surgical oncologist. The relationship between GTVp and local recurrence in the present study is an important information for radiation oncologist.
GTVp was significantly associated with clinical T category in the present study. Although there is an opinion that a multivariate analysis should not include them together, the present study underwent the multivariate analysis due to exclusion of the influence of the confounding factor as reported previously (12) . Survival period is commonly counted from date of initiation of radiotherapy, but the present study counted from the endpoint of radiotherapy.
The present study has some limitations, including small size and a retrospective design. A future prospective study with a large cohort and multi-institutional setting would yield useful results. Statistical analysis leads the GTVp cut-off value as 83.7 ml in the present study, and we guessed useful to adapt this subtle for the practical clinical case after prospective study.
Conclusions
The present study demonstrates that GTVp ≥ 83.7 ml is a predictor of significantly shorter LRFR in patients with sinonasal tract SCC treated by CRT.
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